stockrow
Friday 6 November 2026
Export CTKB’s income statement to Excel — free account
Cytek Biosciences, Inc.
CTKB Healthcare Medical Devices
Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024.
- Revenue
- +1.79%
- EPS
- −25.0%
- Free cash flow
- −30.3%
- Total debt
- −84.9%
Quarter to September 2026, against a year earlier
5.84
0.44
+8.15%
Follow CTKB
Alert me
Cytek Biosciences, Inc. (CTKB) P/E ratio
Cytek Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 5,391× (January 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 541× | (89.39%) |
| FY2021 | 5,100× | 13,919.58% |
| FY2020 | 36.4× | 0.00% |
| FY2019 | 36.4× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
Low 0.0×
High 5,391×
Ten-year median
0.0×
Current reading's percentile
82
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PACB Pacific Biosciences of California, Inc. compare | n/m |
| CTKB Cytek Biosciences, Inc. | n/m |
| BBNX Beta Bionics, Inc. compare | n/m |
| AVR Anteris Technologies Global Corp. compare | n/m |
| KIDS OrthoPediatrics Corp. compare | n/m |
| INMD InMode Ltd. compare | 10.7× |
| BVS Bioventus Inc. compare | 12.3× |
| TCMD Tactile Systems Technology, Inc. compare | 25.2× |
| VREX VAREX IMAGING compare | 34.8× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)